Marketwired .

Subscribe to Marketwired .: eMailAlertsEmail Alerts
Get Marketwired . via: homepageHomepage mobileMobile rssRSS facebookFacebook twitterTwitter linkedinLinkedIn

News Feed Item

PolarityTE(TM) Inc., names World Renowned Plastic & Reconstructive Surgeon Michael W. Neumeister, MD, FRCSC, FACS, as Chief Medical Officer

Dr. Neumeister has previously served as President of the Plastic Surgery Foundation, Plastic Surgery Research Council and a Leader in Translational Regenerative Medicine

SOUTH PLAINFIELD, NJ -- (Marketwired) -- 12/09/16 -- Majesco Entertainment, Inc. (NASDAQ: COOL) ("Majesco") following announcement that it had signed a definitive merger agreement with PolarityTE, Inc. ("Polarity") www.polarityte.com announced it has appointed Michael W. Neumeister, MD, FRCSC, FACS as Chief Medical Officer (http://www.siumed.edu/surgery/plastics/cvs/neumeister_cv.html). Dr. Neumeister was formerly President of the Plastic Surgery Foundation and Plastic Surgery Research Council and is a Leader in Regenerative Medicine (http://www.siumed.edu/surgery/plastics/cvs/MWN%20CV.pdf). Following satisfaction of the conditions to closing, including approval of stockholders, Polarity will be acquired by Majesco, and will operate as a wholly-owned subsidiary of Majesco, which will change its name to Polarity in connection with the contemplated transaction.

"Polarity seeks to alter the paradigms of regenerative medicine and patient-specific tissue engineering for the future. It is with these ambitious goals in mind that I am pleased to announce world renowned plastic and reconstructive surgeon Dr. Michael Neumeister has agreed to join as Chief Medical Officer of PolarityTE™. Beyond his tremendous expertise in some of the most complex reconstructive procedures performed, he has remained a leader and mentor in the field and an innovator in pragmatic translational regenerative medicine," said Chief Executive Officer and Chairman Dr. Denver Lough.

"I am extremely excited to join the Polarity Team and help transform the landscape of translational tissue engineering and reconstructive surgery. I believe I can add tremendous value with a large network of clinical thought leaders and practical viewpoint on the application of the technology. Dr. Lough and I have a close working relationship and I consider him to be one of the most gifted and brilliant innovators in regenerative medicine, and it is an honor to be brought on to his team in this role. I have no doubt, he will change field as we know it," said Dr Neumeister.

About PolarityTE
PolarityTE, Inc. is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by Denver Lough MD, PhD. This radical and proprietary technology employs a patients' own cells for the healing of full-thickness functionally-polarized tissues. If clinically successful, the PolarityTE platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. It is because PolarityTE uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine. More info can be found online at www.polarityte.com. Welcome to the Shift™.

About Michael W. Neumeister, MD, FRCSC, FACS
Professor & Chairman - Department of Surgery
The Elvin G. Zook Endowed Chair in Plastic Surgery
Microsurgery/Research Lab Director
Director: Memorial Medical Center Regional Burn Unit
Director: Memorial Medical Center Wound Center
Southern Illinois University School of Medicine, Springfield, IL

Dr. Neumeister is Professor & Chairman of the Department of Surgery and The Elvin G. Zook Endowed Chair in Plastic Surgery at Southern Illinois University School of Medicine in Springfield, IL. He received his medical degree from the University of Toronto and previously completed a degree in physiology and pharmacology at the University of Western Ontario. Dr. Neumeister began his residency at Dalhousie University in Halifax, Nova Scotia in general surgery and went on to complete his plastic surgery residency at the University of Manitoba. He continued his training as a microsurgery fellow at Harvard University's Brigham & Women's Hospital in Boston and completed a one year hand and microsurgery fellowship at Southern Illinois University School of Medicine.

Dr. Neumeister is board certified in plastic surgery by the Royal College of Surgeons of Canada and the American Board of Plastic Surgery. He has also received his Certificate in (SOTH) Surgery of The Hand. Dr. Neumeister has received awards for presentations given regionally, nationally and internationally, has over 150 book chapters and articles, and has multiple research interests in tissue engineering and regenerative medicine.

Dr. Neumeister is the Editor in Chief of the official AAHS journal HAND. He is the past President of the American Society of Reconstructive Microsurgery, American Association for Hand Surgery, The Plastic Surgery Foundation (The Research Body of The American Society of Plastic Surgeons), Plastic Surgery Research Council, and the Midwest Association of Plastic Surgeons.

His memberships include the American Society of Plastic Surgeons, Plastic Surgery Foundation, Plastic Surgery Research Council, American Association for Hand Surgery, American Society of Reconstructive Microsurgery, American Society for Surgery of the Hand, American Burn Association, American Council of Academic Plastic Surgeons and the American Association of Plastic Surgeons where he also serves as an elected official on several of their committees. Dr. Neumeister has received awards for presentations given regionally, nationally and internationally and has over 150 published manuscripts and book chapters.

Dr. Neumeister's research interests include: allotransplantation, tissue engineering, the role of stem cells in reconstruction, ischemia reperfusion, peripheral nerve, and burn modulation.

Forward-Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements contained in this release relate to, among other things, the Company's ongoing compliance with the requirements of The NASDAQ Stock Market and the Company's ability to maintain the closing bid price requirements of The NASDAQ Stock Market on a post reverse split basis. They are generally identified by words such as "believes," "may," "expects," "anticipates," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports filed with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=3089569

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.